Standout Papers

Regression of cirrhosis during treatment wi... 1996 2026 2006 2016 1.2k
  1. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study (2012)
    Patrick Marcellin, Edward Gane et al. The Lancet
  2. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B (2005)
    George Lau, Teerha Piratvisuth et al. New England Journal of Medicine
  3. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C (2000)
    Stefan Zeuzem, S.V. Feinman et al. New England Journal of Medicine
  4. Long-Term Outcome of Hepatitis C Infection after Liver Transplantation (1996)
    Edward Gane, Bernard Portmann et al. New England Journal of Medicine
  5. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008)
    Yun‐Fan Liaw, Nancy Leung et al. Hepatology International
  6. Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B (2007)
    Ching‐Lung Lai, Edward Gane et al. New England Journal of Medicine
  7. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C (2013)
    Edward Gane, Catherine Stedman et al. New England Journal of Medicine
  8. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy (2020)
    Mindie H. Nguyen, Grace Lai–Hung Wong et al. Clinical Microbiology Reviews
  9. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment (2017)
    Edward Gane, Eric Lawitz et al. New England Journal of Medicine
  10. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial (2024)
    Mark Yarchoan, Edward Gane et al. Nature Medicine
  11. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (2024)
    Peter R. Galle, Thomas Decaens et al. Journal of Clinical Oncology
  12. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study (2025)
    Richard Finn, Baek‐Yeol Ryoo et al. The Lancet Oncology

Immediate Impact

15 by Nobel laureates 10 from Science/Nature 122 standout
Sub-graph 1 of 18

Citing Papers

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
Hepatitis B
2023 Standout
39 intermediate papers

Works of Edward Gane being referenced

Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study
2019
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
2017
and 27 more

Author Peers

Author Last Decade Papers Cites
Edward Gane 17862 17239 2642 438 21.0k
Stanislas Pol 14803 13861 3075 475 18.5k
Eugene R. Schiff 22320 21998 3169 361 28.2k
Norah A. Terrault 19102 20430 1941 451 25.7k
Mark Sulkowski 21923 20077 6058 396 26.2k
George Papatheodoridis 12394 13689 1155 386 16.4k
Robert G. Gish 12038 11998 1631 360 15.5k
Eric Lawitz 10800 11201 2543 309 15.7k
Jia‐Horng Kao 19140 20094 1802 591 22.8k
Geoffrey Dusheiko 14713 14194 2375 278 18.1k
Mitchell L. Shiffman 27265 27020 2743 269 33.5k

All Works

Loading papers...

Rankless by CCL
2026